Bayer enlists Schering-Plough's aid for U.S. marketing

Share this article:

The companies also committed to a co-marketing agreement for future promotion of Schering-Plough's cardiovascular product, Zetia, in Japan. In addition, Bayer HealthCare will build up a new U.S.-based global oncology business unit and refocus its U.S. organization on high-profit specialty and biotech products to form Bayer HealthCare's Specialty Pharmaceuticals business.

Bayer estimates that approximately 1,800 U.S.-based Bayer primary care sales and marketing positions will be impacted, either through transfer to Schering-Plough or through staff reductions.

Bayer's drug products will remain the property and legal responsibility of Bayer and continue to be sold under the Bayer brand names. The agreement covers only those Bayer products already approved, not those in development.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.